| Previous Close | 0.98 |
| Open | 0.97 |
| Day High | 0.99 |
| Day Low | 0.92 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.75 |
| Volume | 50,139 |
| Average Volume | 253,293 |
| Market Cap | 14.06M |
| PE | -1.45 |
| EPS | -0.64 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 1.09 |
| Change | -0.05 |
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumesSUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the t
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
GlobeNewswire Inc.
Feb 10, 2026 2:15 PM GMT
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submissio
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the Ca